Tillotts Pharma continues growth with launch in Benelux
Switzerland-based Tillotts Pharma, part of Japan’s Zeria Group (TYO: 4559), today announced entering new markets in Belgium, the Netherlands and Luxembourg (Benelux).
The development of these markets underlines Tillotts’ commitment in accelerating its expansion in Europe and is expected to continue fuelling strong growth for the group in 2021. In November 2020, Tillotts acquired the rights to Dificlir (fidaxomicin) from Astellas Pharma’s (TYO: 4503) European subsidiary. The drug is for the treatment of Clostridioides difficile infections (CDI), and marks the next important step in opening new affiliates in Europe.
The new structure will allow the company to fully exploit its potential by offering innovative pharmaceutical products in the field of gastroenterology and beyond. Given the geographical proximity, the Benelux organization will be managed by Tillotts Pharma France, which relies on strong expertise within the gastrointestinal therapeutic area working closely together with scientific experts, medical and patients’ organizations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze